NCT01466231 2016-01-12
Everolimus in Refractory Testicular Germ Cell Cancer
National Cancer Institute, Slovakia
Phase 2 Completed
Clinical Trials
5 trialsNCT01525719 2012-02-03
CRAD001T
Ratchavithi Hospital
Phase 2 Unknown
NCT01412515 2012-01-02
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
Institut National de la Santé Et de la Recherche Médicale, France
Phase 2 Terminated
NCT00973713 2009-09-09
RADiChol
Austin Health
Phase 2 Unknown
NCT00657982 2009-01-21
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer
Sheba Medical Center
Phase 2 Unknown